Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in

Author's Avatar
Nov 10, 2022

Presentations highlight use of Nurix’s first-in-class CBL-B inhibitor NX-0255 to enhance growth and profile of T cells for cell therapy in DeTIL-0255 program